Advertisement
U.S. markets closed
  • S&P Futures

    5,183.25
    +15.75 (+0.30%)
     
  • Dow Futures

    38,332.00
    +94.00 (+0.25%)
     
  • Nasdaq Futures

    18,233.00
    +53.75 (+0.30%)
     
  • Russell 2000 Futures

    2,032.60
    +12.80 (+0.63%)
     
  • Crude Oil

    85.62
    -0.04 (-0.05%)
     
  • Gold

    2,378.20
    +4.10 (+0.17%)
     
  • Silver

    28.24
    -0.09 (-0.32%)
     
  • EUR/USD

    1.0652
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    4.4990
    -0.0770 (-1.68%)
     
  • Vix

    17.31
    +2.40 (+16.10%)
     
  • GBP/USD

    1.2459
    +0.0008 (+0.06%)
     
  • USD/JPY

    153.3080
    +0.0680 (+0.04%)
     
  • Bitcoin USD

    65,885.56
    +1,702.06 (+2.65%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,995.58
    +71.78 (+0.91%)
     
  • Nikkei 225

    39,523.55
    0.00 (0.00%)
     

Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics

OrthoPediatrics (KIDS) reported $39.97 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 14.4%. EPS of -$0.13 for the same period compares to -$0.05 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $40.26 million, representing a surprise of -0.72%. The company delivered an EPS surprise of +35.00%, with the consensus EPS estimate being -$0.20.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product sales by category- Trauma and deformity: $28.81 million versus the three-analyst average estimate of $27.68 million. The reported number represents a year-over-year change of +20.5%.

  • Product sales by category- Sports medicine/other: $0.86 million versus the three-analyst average estimate of $1.19 million. The reported number represents a year-over-year change of -21.6%.

  • Product sales by category- Scoliosis: $10.30 million versus $11.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3% change.

View all Key Company Metrics for OrthoPediatrics here>>>

Shares of OrthoPediatrics have returned -8.3% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OrthoPediatrics Corp. (KIDS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement